Recombinant adeno-associated virus serotype 2-mediated RNA interference inhibits rabies virus replication

Abstract

Rabies virus (RABV) is a neurotropic virus that infects the central nervous systems of humans and animals, causing fatal neurological symptoms and ultimately death. Vaccination is the only effective strategy for preventing rabies. However, once clinical symptoms appear, there is no effective treatment. Therefore, exploring effective therapeutic approaches, particularly for postexposure prophylaxis, is imperative. This study investigated the inhibitory effect of siRNA delivered by recombinant adeno-associated virus serotype 2 (rAAV2) against RABV. Specific siRNAs targeting the mRNA of the G and L genes of the RABV were designed. rAAV-G997 and rAAV-L5055 were constructed with siRNA expression cassettes. Pretreatment of neuroblastoma (NA) cells with either rAAV-G997 or rAAV-L5055 before RABV infection resulted in a considerable reduction in both the viral titer and the mRNA levels of the G and L genes. Similarly, pretreatment of baby hamster kidney (BHK-21) cells with rAAV-G997 or rAAV-L5055 prior to RABV infection decreased the expression of viral structural proteins. In a mouse model, compared with the negative control (rAAV-NC), the intracranial administration of rAAV-G997 or rAAV-L5055 conferred significant protection. When administered before challenge with the RABV CVS-11 strain, both rAAV-G997 and rAAV-L5055 significantly reduced the viral load in brain tissue, and achieved a survival rate of 90%. Similarly, in a postexposure treatment setting, both the rAAV-G997 and rAAV-L5055 groups achieved a survival rate of 88.9%. These findings demonstrate that rAAV-mediated delivery of siRNAs targeting the RABV G and L genes can inhibit viral replication in vitro and provide significant protection in vivo, highlighting the potential of rAAV2 as a therapeutic platform for treating rabies.

Keywords

Rabies / Adeno-associated virus / siRNA / G gene / L gene

References

[1] Amendola M, Passerini L, Pucci F, Gentner B, Bacchetta R, Naldini L. Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Molecular Therapy, 2009, 17(6): 1039-1052

[2] Bauer A, Nolden T, Schröter J, Römer-Oberdörfer A, Gluska S, Perlson E, Finke S. Anterograde glycoprotein-dependent transport of newly generated rabies virus in dorsal root ganglion neurons. Journal of Virology, 2014, 88(24): 14172-14183

[3] Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Efficient gene transfer of HIV-1-specific short hairpin RNA into human lymphocytic cells using recombinant adeno-associated virus vectors. Molecular Therapy, 2004, 9(3): 396-402

[4] Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clinical Microbiology Reviews, 2008, 21(4): 583-593

[5] Delmas O, Holmes EC, Talbi C, Larrous F, Dacheux L, Bouchier C, Bourhy H. Genomic diversity and evolution of the lyssaviruses. PLoS ONE, 2008, 3(4 e2057

[6] Dodet B, Tejiokem MC, Aguemon AR, Bourhy H. Human rabies deaths in Africa: Breaking the cycle of indifference. International Health, 2015, 71): 4-6

[7] Ebberink EHTM, Ruisinger A, Nuebel M, Thomann M, Heck AJR. Assessing production variability in empty and filled adeno-associated viruses by single molecule mass analyses. Mol. ther. Methods Clin. Dev., 2022, 27: 491-501

[8] Fooks AR, Banyard AC, Horton DL, Johnson N, McElhinney LM, Jackson AC. Current status of rabies and prospects for elimination. Lancet, 2014, 384(9951): 1389-1399

[9] Gong Y, Chen SZ, Sonntag CF, Sumners C, Klein RL, King MA, Hughes JA, Meyer EM. Recombinant adeno-associated virus serotype 2 effectively transduces primary rat brain astrocytes and microglia. Brain Research Protocols, 2004, 14(1): 18-24

[10] Gong XQ, Gao HT, Wang WY, Xu TH. Intramuscular injection of rAAV2-retro for low motor neuron transduction: Evaluating five promoters. International Journal of Medical Sciences, 2025, 22(4): 775-789

[11] Gupta S, Schoer RA, Egan JE, Hannon GJ, Mittal V. Inducible, reversible, and stable RNA interference in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(7): 1927-1932

[12] He H, Cai T, Chen Q, Chen Z, Zhang B, Chen C, Wang Y, Liu Y, Wang Y, Luo Y, Huang S, Luo J, Guo X. Trim44 promotes rabies virus replication by autophagy-dependent mechanism. International Journal of Molecular Sciences, 2024, 25(9): 4616

[13] He H, Liang W, Lin W, Wang Y, Su R, Wang Y, Huang S, Luo J, Guo X. Trim7 inhibits rabies virus replication by promoting k48-linked ubiquitination and degradation of RABV-M. Emerg. Microbes & Infect., 2026, 15(1): 2667557

[14] Huang Y, Jiao SZ, Tao XY, Tang Q, Jiao WT, Xiao J, Xu XY, Zhang YB, Liang GD, Wang HY. Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection. Journal of Neuroinflammation, 2014, 11: 146

[15] Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Research, 2013, 99(1): 61-67

[16] Kandel, R., Subedi, A., Adhikari, S. 2024. Agile and reactive rabies vaccination techniques in countries with low and middle incomes. Animal Diseases 4: 13. https://doi.org/10.1186/s44149-024-00121-2.

[17] Khanna M, Saxena L, Rajput R, Kumar B, Prasad R. Gene silencing: A therapeutic approach to combat influenza virus infections. Future Microbiology, 2015, 10(1): 131-140

[18] Kim SM, Lee KN, Lee SJ, Ko YJ, Lee HS, Kweon CH, Kim HS, Park JH. Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus. Antiviral Research, 2010, 87(3): 307-317

[19] Kimura T, Ferran B, Tsukahara Y, Shang Q, Desai S, Fedoce A, Pimentel DR, Luptak I, Adachi T, Ido Y, Matsui R, Bachschmid MM. Production of adeno-associated virus vectors for in vitro and in vivo applications. Science and Reports, 2019, 9(1): 13601

[20] Kong WH, Bae KH, Jo SD, Kim JS, Park TG. Cationic lipid-coated gold nanoparticles as efficient and noncytotoxic intracellular siRNA delivery vehicles. Pharmaceutical Research, 2012, 29(2): 362-374

[21] Lei CF, Yang J, Hu J, Sun XL. On the calculation of TCID50 for quantitation of virus infectivity. Virologica Sinica, 2021, 36(1): 141-144

[22] Luo J, Zhang Y, Zhang Q, Wu YT, Zhang BY, Mo MJ, Tian Q, Zhao J, Mei MZ, Guo XF. The deoptimization of rabies virus matrix protein impacts viral transcription and replication. VIRUSES-BASEL, 2020, 12(1): 4

[23] Meshram CD, Singh NK, Sonwane AA, Pawar SS, Mishra BP, Chaturvedi VK, Saini M, Singh RP, Gupta PK. Evaluation of single and dual siRNAs targeting rabies virus glycoprotein and nucleoprotein genes for inhibition of virus multiplication in vitro. Archives of Virology, 2013, 158(11): 2323-2332

[24] Mietzsch M, Smith JK, Yu JC, Banala V, Emmanuel SN, Jose A, Chipman P, Bhattacharya N, McKenna R, Agbandje-McKenna M. Characterization of AAV-specific affinity ligands: Consequences for vector purification and development strategies. Mol. ther. Methods Clin. Dev., 2020, 19: 362-373

[25] Ngugi JN, Maza AK, Omolo OJ, Obonyo M. Epidemiology and surveillance of human animal-bite injuries and rabies postexposure prophylaxis, in selected counties in Kenya, 2011–2016. BMC Public Health, 2018, 18: 996

[26] Ono EAD, Taniwaki SA, Brandao P. Short interfering RNAs targeting a vampire-bat related rabies virus phosphoprotein mRNA. Brazilian Journal of Microbiology, 2017, 48(3): 566-569

[27] Pei X, Earley LF, He Y, Chen X, Hall NE, Samulski RJ, Li C. Efficient capsid antigen presentation from adeno-associated virus empty virions&it in vivo&it. Frontiers in Immunology, 2018, 9: 844

[28] Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE, Meleth S. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: Long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Research, 2004, 64(5): 1781-1787

[29] Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: Similarities and differences. Advanced Drug Delivery Reviews, 2009, 61(9): 746-759

[30] Raouane M, Desmaële D, Urbinati G, Massaad-Massade L, Couvreur P. Lipid conjugated oligonucleotides: A useful strategy for delivery. Bioconj. Chem., 2012, 23(6): 1091-1104

[31] Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. Journal of Virological Methods, 2002, 106(1): 81-88

[32] Rupprecht CE, Salahuddin N. Current status of human rabies prevention: Remaining barriers to global biologics accessibility and disease elimination. Expert Review of Vaccines, 2019, 18(6): 629-640

[33] Sharifi BG, Wu KJ, Wang L, Ong JM, Zhou XH, Shah PK. AAV serotype-dependent apolipoprotein A-IMilano gene expression. Atherosclerosis, 2005, 181(2): 261-269

[34] Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Molecular Therapy, 2020, 28(3): 709-722

[35] Sonwane AA, Dahiya SS, Saini M, Chaturvedi VK, Singh RP, Gupta PK. Inhibition of rabies virus multiplication by siRNA delivered through adenoviral vector in vitro in BHK-21 cells and in vivo in mice. Research in Veterinary Science, 2012, 93(1): 498-503

[36] Taxman DJ, Livingstone LR, Zhang JH, Conti BJ, Iocca HA, Williams KL, Lich JD, Ting JPY, Reed W. Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnology, 2006, 6 7

[37] Tenenbaum L, Chtarto A, Lehtonen E, Velu T, Brotchi J, Levivier M. Recombinant AAV-mediated gene delivery to the central nervous system. Journal of Gene Medicine, 2004, 6: S212-S222

[38] Wang YY, Chen X, Tian BQ, Liu JF, Yang L, Zeng LL, Chen TF, Hong A, Wang XG. Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics, 2017, 7(5): 1360-1372

[39] Wang, Y. and Shao, W. 2023. Innate immune response to viral vectors in gene therapy. Viruses-Basel 15(9). https://doi.org/10.3390/v15091801.

[40] Whitehead KA, Langer R, Anderson DG. Erratum: Knocking down barriers: Advances in siRNA delivery. Nature Reviews. Drug Discovery, 2009, 8(6): 516-516

[41] Wong B, Birtch R, Rezaei R, Jamieson T, Crupi MJF, Diallo JS, Ilkow CS. Optimal delivery of RNA interference by viral vectors for cancer therapy. Molecular Therapy, 2023, 31(11): 3127-3145

[42] Wu HX, Wang HL, Guo XF, Yang YJ, Ma JZ, Wang TC, Gao YW, Zhao YK, Yang ST, Xia XZ. Adeno-associated viruses serotype 2-mediated RNA interference efficiently inhibits rabies virus replication in vitro and in vivo. Journal of Veterinary Medical Science, 2013, 75(10): 1355-1361

[43] Xia XG, Zhou HX, Ding HL, Affar EB, Shi Y, Xu ZS. An enhanced U6 promoter for synthesis of short hairpin RNA. Nucleic Acids Research, 2003, 31(17): 100e-100

[44] Yang YJ, Zhao PS, Zhang T, Wang HL, Liang HR, Zhao LL, Wu HX, Wang TC, Yang ST, Xia XZ. Small interfering RNAs targeting the rabies virus nucleoprotein gene. Virus Research, 2012, 169(1): 169-174

[45] Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Reports, 2003, 4(6): 602-608

[46] Zhang H, Huang J, Song Y, Liu X, Qian M, Huang P, Li Y, Zhao L, Wang H. Regulation of innate immune responses by rabies virus. Animal Models and Experimental Medicine, 2022, 5(5): 418-429

[47] Zhang Y, Zhang M, Liao X, Yu Y, Liu Q, Luo Y, Luo J, Guo X. Interleukin-25 enhances humoral immune responses caused by the rabies virus. Virulence, 2022, 13(1): 1446-1454

[48] Zheng WW, Zhu XX, Zhu TT, Luo Q, Zhao Y, Xu TJ. A novel protein nlrp12-119aa that prevents rhabdovirus replication by disrupting the RNP complex formation. Advanced Science, 2025, 1212 2409953

Funding

National Nature Science Foundation of China(32473115)

Undergraduate Research Project of South China Agricultural University(202410564069)

National Key Research and Development Plan(2022YFD1800100)

Guangdong Basic and Applied Basic Research Foundation(2024A1515010961)

Specific University Discipline Construction Project(2023B10564003)

RIGHTS & PERMISSIONS

The Author(s)